News

Article

MDMA-Assisted Psychotherapy: The Science Is What Matters

Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.

In this Mental Health Minute video, Ingmar Gorman, PhD, discusses his clinical research experience with MDMA-assisted psychotherapy. While disappointed about the US Food and Drug Administration's decision to issue a complete response letter for this treatment, he believes the science behind MDMA-assisted psychotherapy is what matters most. Participants encountered very difficult material during the treatment process, Gorman shares, but a majority saw clinical benefit.

Dr Gorman is a study therapist in the phase 3 clinical trial for MDMA-assisted therapy and a co-founder of Fluence, a psychedelic education company that trains mental health providers in psychedelic treatments.

Related Videos
John J. Miller, MD
John J. Miller, MD
John J. Miller, MD
John J. Miller, MD
John J. Miller, MD
John J. Miller, MD
PTSD
© 2024 MJH Life Sciences

All rights reserved.